Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a regulatory, glycoprotein necessary for the proliferation, maturation, and survival of myeloid cells [4] . Myelopoiesis is enhanced when recombinant human (rh) GM-CSF is given to mice, monkeys [6] , and some patients with various forms of neutropenia [3, 5] . The clinical use of rhGM-CSF infusions is under intensive investigation now.
An alternative way of increasing the level of GM-CSF in the organism is by transplantation of CSF -producing cells, analogous to the transplantation of insulin-producing cells in patients with diabetes mellitus. It seems especially important to increase the intramedullary concentration of GM-CSF, as bone marrow is the central organ for regulating the proliferation and differentiation of hematopoietic cells. There is a positive correlation between the intramedullary concentration of GM-CSF and the prognosis for patients with leukemia [8] . One source of CSF-producing cells may be various embryonal cells which are available and genetically more tolerable.
The main objectives of this study were: (a) to evaluate the ability of various human fetal organs and tissues to develop colony-stimulating and -inhibiting activities (CSA and CIA); (b) to estimate their effect on colony-forming unit-granulocyte macrophage (FU-GM) and leukemic clonogenic cells (LCC); (c) to evaluate the effect of fetal bone (FB) on fibrous tissue of adult bone marrow in N.N. Petrov Institute of Oncology, Department of Bone Marrow Transplantation, Leningrad, USSR vitro; and (d) to evaluate the effect of rat FB transplantation into rats after lethal and sublethal doses of cyclophosphamide.
A. Material and Methods
A total of 88 human fetuses (24 at 7-10 weeks; 38 at 11-15 weeks; 22 at 20-26 weeks) were used to evaluate CSA and CIA of various fetal organs and condition media (CM). Bone marrow cells of 87 hematologically healthy donors (control group), 92 patients with various hematological disorders, and 48 human fetuses (7 at 10-12 weeks; 10 at 13-15 weeks; 16 at 20-22 weeks; 15 at 23-26 weeks) were used as target cells. The cloning of hematopoietic cells was performed in agar drop-liquid medium [1] . CSA of fetal tissues (FT) or CM (CMFT) was estimated as: the number of aggregates in the plates with FB or CMFT divided by the number of aggregates in the plates with leukocyte feeder (F). IA was calculated as; CSA of F (100%) -CSA of (F + FT or CMFT).
Colonies and clusters were scored at day 7 or 8. The effect of FB on fibrous tissue was studied by morphometric assay of bone marrow trephine biopsy after its cultivation using the Marbrook system [2] with or without FB. The scheme of rat FB transplantation is presented in Fig. 1 .
B. Results and Discussion
All human fetal tissues except from the liver were able to produce CSA in vitro cryopreservation at -196° C with 10% DMSO did not considerably affect its capacity for CSA production (Fig. 3) . The transplantation of FB shortened the period of leukocytopenia after sublethal (300 mg/kg) or lethal (500 mg/kg) doses of cyclophosphamide in a rat model (Fig. 4) and increased the probability of survival (Fig. 5) .
Thus, rat survival after FB transplantation was increased. This effect is proba- bly related to the ability of FB to give long-term CSF production and the increase of the intramedullary CSF level. We have shown that FB induced the proliferation of LCC. FB has been suggested to exert a differentiated effect on LCC, which can return to their normal phenotype [7] . Moreover, FB inhibits fibrous tissue proliferation in human AML bone marrow. Further research is needed to establish the place of FB transplantation in clinical practice.
185 Table 2 . Results of cultivation of bone marrow tissue in Marbrook system in the presence of human fetal bone (morphometric assay bone marrow trephine biopsies from the acute nonlymphocytic leukemia patients) Solid curve, experimental group (n = 63);
broken curve, control group (n = 42)
